Press Releases

Page 1 of 56

Pages

to
December 15, 2014

NIH recruits three Lasker Clinical Research Scholars

The National Institutes of Health has selected three researchers as new Lasker Clinical Research Scholars as part of a joint initiative with the Albert and Mary Lasker Foundation to nurture the next generation of great clinical scientists.

October 27, 2014

NIH and CDC Announce Grantees for the Sudden Death in the Young Registry

The NIH and CDC announce awards to ten grantees for the Sudden Death in the Young Registry. Six are current or former grantees from the Sudden Unexpected Infant Death (SUID) Registry: Georgia, Michigan, Minnesota, New Hampshire, New Jersey, and Wisconsin. Four are new grantees: Delaware, Tennessee, the city of San Francisco and the Tidewater region of Virginia.

September 12, 2014

NIH awards aim to improve understanding of cell pathways, development of new therapies

Building on a successful three-year pilot project, the National Institutes of Health has awarded more than $64 million to six research institutions to create a database of human cellular responses, the Library of Integrated Network-based Cellular Signatures (LINCS).  Discovering such cell responses will improve scientists’ understanding of cell pathways and aid in the development of new therapies for many diseases.

July 1, 2014

Adults stop anti-rejection drugs after partial stem-cell transplant reverses sickle cell disease

Half of patients in a trial have safely stopped immunosuppressant medication following a modified blood stem-cell transplant for severe sickle cell disease, according to a study in the July 1 issue of the Journal of the American Medical Association. The trial was conducted at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, by researchers from NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart, Lung, and Blood Institute.

May 19, 2014

Common treatment for patients with chronic, progressive lung disease found to be ineffective

A drug used to treat patients with mild to moderate lung damage from the disease idiopathic pulmonary fibrosis (IPF) is no better than placebo for preserving lung function, according to a study supported by the National Institutes of Health.
The finding is in the final report of a clinical trial called Prednisone, Azathioprine, and N-Acetylcysteine: A Study That Evaluates Response in Idiopathic Pulmonary Fibrosis (PANTHER-IPF).

Page 1 of 56

Pages

Subscribe to NHLBI Press Releases